We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$5B
AUM Growth
-$515M
Cap. Flow
-$868M
Cap. Flow %
-17.36%
Top 10 Hldgs %
42.58%
Holding
90
New
18
Increased
21
Reduced
23
Closed
27

Top Buys

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$221M
2
NFLX icon
Netflix
NFLX
+$154M
3
AGN
Allergan Inc
AGN
+$138M
4
MLM icon
Martin Marietta Materials
MLM
+$125M
5
VMC icon
Vulcan Materials
VMC
+$121M

Top Sells

Rank Stock Value
1
EEM icon
iShares MSCI Emerging Markets ETF
EEM
+$439M
2
BMY icon
Bristol-Myers Squibb
BMY
+$401M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$230M
4
ENDP
Endo International plc
ENDP
+$155M
5
WDAY icon
Workday
WDAY
+$122M

Sector Composition

Rank Sector Weight
1 Healthcare 37.84%
2 Communication Services 11.85%
3 Materials 8.94%
4 Consumer Discretionary 8.09%
5 Technology 7.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
76
CALL
Teva Pharmaceuticals
TEVA
$35.9B
– –
-404,100
Closed -$570K
TXMD icon
77
TherapeuticsMD
TXMD
$23.8M
– –
-48,315
Closed -$15.2M
WDAY icon
78
Workday
WDAY
$33.4B
– –
-1,339,125
Closed -$122M
WYNN icon
79
Wynn Resorts
WYNN
$10.1B
– –
-470,123
Closed -$104M
YELP icon
80
Yelp
YELP
$1.38B
– –
-363,207
Closed -$27.9M
ICPT
81
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-66,571
Closed -$22M
ACOR
82
DELISTED
Acorda Therapeutics
ACOR
– –
-6,030
Closed -$27.4M
ENDP
83
DELISTED
Endo International plc
ENDP
– –
-2,252,173
Closed -$155M
CSLT
84
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-96,223
Closed -$2.04M
APC
85
DELISTED
Anadarko Petroleum
APC
– –
-212,833
Closed -$18M
DATA
86
DELISTED
Tableau Software, Inc.
DATA
– –
-363,753
Closed -$27.7M
YHOO
87
DELISTED
Yahoo Inc
YHOO
– –
-2,476,788
Closed -$88.9M
FRX
88
DELISTED
FOREST LABORATORIES INC
FRX
– –
-83,033
Closed -$7.66M
TWC
89
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
– –
-867,468
Closed -$119M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2014 Portfolio in Review

As of Q2 2014, PFM Health Sciences held 90 positions worth $5B, down 9.3% from $5.52B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

PFM Health Sciences withdrew a net $868M in Q2 2014, closing 27 positions and reducing 23 holdings. Its most notable exit was iShares MSCI Emerging Markets ETF, an estimated $439M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 46% a quarter earlier, followed by Communication Services and Materials.

Against the trend, PFM Health Sciences opened a new position in Netflix worth $179M.

  • PFM Health Sciences's largest Q2 2014 buy was Netflix: 28,445,060 shares worth $179M.
  • PFM Health Sciences added most to Rite Aid Corporation in Q2 2014, an estimated $221M increase.
  • PFM Health Sciences's biggest Q2 2014 reduction was Alphabet (Google) Class C, cutting an estimated $230M.
  • PFM Health Sciences fully exited iShares MSCI Emerging Markets ETF in Q2 2014, selling an estimated $439M.
  • PFM Health Sciences's ten largest holdings make up 43% of its $5B portfolio in Q2 2014.
  • PFM Health Sciences opened 18 new positions and closed 27 in Q2 2014.
  • PFM Health Sciences's portfolio value fell 9.3% quarter-over-quarter to $5B.

Based on PFM Health Sciences's 13F filing for Q2 2014, filed 14 Aug 2014.